Literature DB >> 9777294

Prevalence of hypercalcaemia in normal and in hospital populations.

A Frølich1.   

Abstract

The purpose of the present study was to review the literature with respect to the prevalence of hypercalcaemia in normal and in hospital populations. Pertinent studies were selected from the MEDLINE database (1980 to March 1995) and through the bibliographies of selected articles. Hypercalcaemia is one of the most common metabolic disorders in malignant diseases and develops in 3-30% of such patients. Hypercalcaemia of malignancy is the most common cause of hypercalcaemia followed by primary hyperparathyroidism in hospital populations. The most common cause in normal populations is primary hyperparathyroidism followed by transient hypercalcaemia. The prevalence of hypercalcaemia shows a large variation in hospital populations ranging from 0.17% to 2.92%. The prevalence in normal populations varies between 1.07% and 3.9% and, surprisingly exceeds the level in hospital populations. The discrepancies between prevalences may be due to varying referral patterns, different distribution of specialities causing different hospital populations and different definitions of hypercalcaemia. Hypercalcaemia presents a diagnostic problem. The percentage of cases of hypercalcaemia that are actually diagnosed has been observed to be as low as 25% in hospitals, in which laboratory results remain unreported unless requested. But even when presented, 20-50% of the cases are overlooked.

Entities:  

Mesh:

Year:  1998        PMID: 9777294

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  9 in total

Review 1.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

2.  The changing profile of hypercalcemia in a tertiary care setting in North India: an 18-month retrospective study.

Authors:  Mohammad Shafi Kuchay; Parjeet Kaur; Sunil Kumar Mishra; Ambrish Mithal
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

3.  A Retrospective Study of Serum Calcium Status in Tehran, Iran (105,128 Samples, from 2009-2018).

Authors:  Dariush D Farhud; Marjan Zarif-Yeganeh; Atefeh Mehrabi; Ali-Reza Afshari; Mohammad Bagher Rokni; Keyvan Majidi; Maryam Jalali; Ali Akbar Amir Zargar; Abdolfattah Sarafnejad; Hamid Reza Sadeghipour; Shaghayegh Zokaei; Farideh Khosravi; Mahmoud Jalali; Mohammad Khazeni
Journal:  Iran J Public Health       Date:  2022-04       Impact factor: 1.479

4.  Prevalence of hypercalcemia in hospitalised patients: effects of "correction" for serum albumin values.

Authors:  V Carnevale; M Pipino; M Antonacci; C Checchia; V D'Alessandro; M Errico; A Greco; A Varriale
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

5.  Severe refractory hypercalcaemia in HTLV-1 infection.

Authors:  C Mark B Edwards; Sarah J E Edwards; Rej-Paul Bhumbra; Tahseen A Chowdhury
Journal:  J R Soc Med       Date:  2003-03       Impact factor: 18.000

6.  Treatment of immobilization-related hypercalcaemia with denosumab.

Authors:  Fabio Malberti
Journal:  Clin Kidney J       Date:  2012-11-04

7.  Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?

Authors:  A Catalano; D Chilà; F Bellone; G Nicocia; G Martino; I Loddo; N Morabito; S Benvenga; S Loddo
Journal:  J Clin Transl Endocrinol       Date:  2018-05-29

8.  Frequency of Parathyroid Hormone Assessment in the Evaluation of Hypercalcemia. A Comparison Between Patients With and Without a History of Malignancy in a 20-year Dataset of 20,954 Patients.

Authors:  Michael T Sheehan; Ya-Huei Li; Suhail A Doi; Adedayo A Onitilo
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-11-24

9.  Assessment of serum electrolytes and kidney function test for screening of chronic kidney disease among Ethiopian Public Health Institute staff members, Addis Ababa, Ethiopia.

Authors:  Meseret Derbew Molla; Maria Degef; Abebe Bekele; Zeleke Geto; Feyissa Challa; Tadesse Lejisa; Tigist Getahun; Meron Sileshi; Yosef Tolcha; Genet Ashebir; Daniel Seifu
Journal:  BMC Nephrol       Date:  2020-11-18       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.